Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

44.7 USD

Average target price

54.02 USD

Spread / Average Target

+20.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-12.59%	90.6B
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
44.85 ^USD	+0.34%		-8.73%	-12.59%

Apr. 26	S&P 500 Q1 earnings estimated growth improves; stocks up for week	RE
Apr. 26	Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	MT

S&P 500 Q1 earnings estimated growth improves; stocks up for week	Apr. 26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	Apr. 26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	Apr. 26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	Apr. 26	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	Apr. 26	MT
Bristol Myers: positive opinion from the CHMP for Opdivo	Apr. 26	CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer	Apr. 26	DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	Apr. 26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	Apr. 26	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	Apr. 26	MT
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Sector Update: Health Care	Apr. 25	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	Apr. 25	MT
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall	Apr. 25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
Stocks in motion: Large caps struggle	Apr. 25
Trending : Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts	Apr. 25	DJ
The specter of stagflation rears its ugly head again	Apr. 25
Bristol Myers Shedding 2,200 Jobs in Cost Savings Push	Apr. 25	DJ
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance	Apr. 25	MT
Bristol Myers: heavy quarterly loss on charges	Apr. 25	CF